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The Role of Gefitinib Treatment for Korean Never-Smokers
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Purpose: This prospective trial was conducted to evaluate the role
of gefitinib in never-smokers with advanced or metastatic adenocar-
cinoma of the lung.
Patients and Methods: The main inclusion criteria were stage
IIIB/IV adenocarcinoma of the lung and status as a lifetime never-
smoker. Patients received a 250-mg single oral daily dose of ge-
fitinib until disease progression, unacceptable toxicity, or patient’s
refusal. Tumor response was assessed after every two 4-week cycles
according to the World Health Organization response criteria. Ad-
ditional analyses were performed to identify predictors of response
and survival.
Results: Between August 2003 and March 2005, 72 Korean patients
were enrolled; 55 chemotherapy naive, 17 previously treated; 6
male, 66 female; and ECOG PS 0/1/2, 24/42/4. All patients were
assessed for response, toxicity, quality of life, and survival. Overall
objective tumor response rate was 55.6% (95% confidence interval
[CI], 43.4–67.3%). With a median follow-up of 23 months, the
median survival time was 19.7 months (95% CI, 18.5–21.0 months)
with a 1-year survival rate of 76.3%. The median duration of
response was 6.8 months (95% CI, 4.7–9.0 months). Therapy-related
improvement of symptoms and quality of life was observed within
2 to 4 weeks after the commencement of therapy in the responders.
In a multivariate Cox proportional hazard model, good performance
status and no prior history of chemotherapy were the two significant
predictors of better survival (p  0.005 and 0.042).
Conclusion: Gefitinib showed very promising antitumor activity and
survival outcome in Korean never-smokers with adenocarcinoma of the
lung. It seems to be a good alternative to standard chemotherapy as a
first-line therapy for this subgroup.
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Gefitinib, an epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor, is a molecular-targeted agent
approved for use as salvage therapy in advanced non-small
cell lung cancer (NSCLC).1 Two phase II trials showed
clinically significant antitumor activity with rapid symptom
relief and improvements in quality of life as second- and
third-line treatment in NSCLC patients, which are compara-
ble with the result of docetaxel, currently considered the
standard therapy in the salvage setting.2–4 The enthusiasm
generated by the initial results were attenuated by the phase
III trials that showed neither survival benefit nor improved
response rate when given together with standard combination
chemotherapy.5–6 Furthermore, the final results of the Iressa
Survival Evaluation in Lung Cancer trial, which failed to
confirm the survival benefit of gefitinib treatment over pla-
cebo in patients with previously treated NSCLC,7 further
dampened the interest in the use of gefitinib in the United
States and Europe.
Nevertheless, retrospective analyses suggested that cer-
tain clinicopathologic parameters, that is, adenocarcinoma or
bronchioloalveolar pathologic subtype, never-smoking his-
tory, and East Asian ethnicity were the predictors of gefitinib
responsiveness.2,3,8 Prompted by those clinical observations,
in August 2003 we initiated a prospective trial to evaluate the
efficacy of gefitinib monotherapy in a front-line and second-
line setting in Korean never-smokers with adenocarcinoma of
the lung. We previously reported on the results of the first 37
chemotherapy-naive patients after a median follow-up of 48
weeks (range, 4–70 weeks).9 Of the 37 patients enrolled, 36
were assessed for response and 25 (69%) had partial re-
sponse. Although the median survival time was not reached at
the time of report, the estimated 1-year survival rate was
73%, and the median progression-free survival was 33 weeks.
With more patients enrolled and a longer follow-up, we
report mature data, including the median survival times
stratified by the status of prior chemotherapy exposure, which
further support the role of gefitinib monotherapy in this
subgroup of Korean patients with adenocarcinoma of the lung.
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PATIENTS AND METHODS
Eligibility Criteria
The main eligibility criteria were stage IIIB with pleu-
ral effusion or pericardial effusion or IV advanced or meta-
static adenocarcinoma of the lung according to the World
Health Organization’s (WHO) classification,10 and lifetime
never-smoker status, defined as having smoked no more than
100 cigarettes during one’s lifetime. Additional criteria were
as follows: 1) age of 18 to 75 years; 2) Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 2; 3)
bidimensionally measurable lesion(s) on computed tomogra-
phy scan; 4) adequate bone marrow, hepatic, and renal
function, defined as white blood cell count 4.0  109/liter,
neutrophils 2.0  109/liter, platelets 100  109/liter,
hemoglobin 10 mg/dl, alanine aminotransferase or aspar-
tate aminotransferase 2.5 times the upper normal limit,
serum bilirubin 1.2 mg/dl, and serum creatinine 1.5
mg/dl; 5) no prior chemotherapy or having received only one
regimen of combination chemotherapy; and 6) no prior mo-
lecular-targeted therapy. Brain metastasis was allowed, pro-
vided that there had been no clinically significant neurologic
symptoms or signs. All patients gave a written informed
consent approved by the institutional review board of the
National Cancer Center. The study followed the Declaration
of Helsinki and good clinical practice guidelines.
Treatment Plan
Patients received a single oral daily dose of 250 mg of
gefitinib until disease progression, unacceptable toxicity, or
patient’s refusal. Each cycle consisted of 4 weeks of therapy,
and interruption of gefitinib therapy was allowed for a max-
imum of 2 weeks. As a baseline, a complete history and
physical examination, including documentation of concomi-
tant medications, performance status and history of smoking,
standard laboratory studies, and electrocardiogram were per-
formed within 14 days before the study entry. Chest x-ray,
computed tomography scans of the chest including the upper
abdomen, magnetic resonance imaging of the brain, and a
radionuclide bone scan were done within 4 weeks before the
study entry. Pathologic evaluation was primarily based on the
WHO’s classification.10 However, because BAC histology
was suggested to be an independent predictor of tumor
response, all pathology slides and cytology were prospec-
tively reviewed by a referee pathologist (EKH) to identify the
two subgroups of adenocarcinoma: those with BAC features,
and those without, as proposed by Ebright et al.11
Criteria for Evaluation of Efficacy
The primary endpoint of the study was objective tumor
response, which was assessed according to the WHO criteria
after each cycle by chest x-ray and every two cycles by
computed tomography scans and magnetic resonance imag-
ing where appropriate.12 The tumor responses in the brain
were also assessed using the same diagnostic technique as in
the baseline assessment and compared with the response in
the extracranial sites. All tumor responses were reviewed
independently and confirmed by a referee radiologist (HYK).
Complete response (CR) involved the complete disappear-
ance of all measurable and evaluable disease. Partial response
(PR) was defined as a decrease of at least 50% in the sum of
the products of the maximal perpendicular dimensions of
measurable lesions, with no progression of evaluable disease
and no new lesions. Stable disease (SD) demonstrated no new
lesion or progression of current lesions for a period longer
than 4 weeks. Progression (PD) included patients who had
clear worsening of any evaluable disease, the development of
new lesions, recurrence of lesions that had previously disap-
peared, or failure to return for evaluation because of deteri-
oration. Patients were evaluated weekly for toxicity during
the first cycle and then every 4 weeks thereafter using the
National Cancer Institute Common Toxicity Criteria version
2.0.13
Quality of Life
Quality of life (QoL) was measured using the European
Organization for Research and Treatment of Cancer Quality
of Life Questionnaire C30, version 3.0.14 An additional lung
cancer module, QoL Questionnaire LC13, was used.15 All of
the scales and single-item measures range in score from 0 to
100; a high score represents a higher response level. Thus, a
high score for a functional scale and the global health status
represents a healthy level of functioning and high quality of
life, but a high score for a symptom scale or item represents
a high level of symptomatology. The QoL questionnaire was
administered at baseline, every week during the first cycle,
every cycle thereafter, and at the end of study. The question-
naire was to be completed during office visits before any
other evaluations or assessment of adverse events. Changes in
QoL scores during the study were compared with the baseline
score.
Statistical Consideration
This was a single-arm, open-labeled, prospective, sin-
gle-center study. All patients were included in all efficacy and
safety analyses. The parameters of interest are estimated and
presented with their 95% confidence intervals using exact
binomial probabilities. Duration of response was defined as
the interval between the date of documented response and the
date of documented disease progression. Progression-free
survival was defined as the interval between the date of the
start of treatment and the date of documented disease pro-
gression or death from any cause. Overall survival was also
defined as the interval between the date of the start of
treatment and the date of death from any cause. If a patient
was lost to follow-up, that patient was censored at the last
date of contact. All time-to-event variables were analyzed
using Kaplan–Meier product-limit survival estimates. Pre-
treatment characteristics were analyzed in multivariate logis-
tic regression models for their ability to predict objective
response and in multivariate Cox proportional hazards mod-
els for their ability to predict survival. Multivariate models
were constructed using backward elimination methods, pos-
sible association with objective response, or survival out-
comes. Changes in QoL scores from baseline score were
evaluated using a paired t test. Data were updated as of
January 10, 2006.
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RESULTS
Patient Characteristics
Between August 2003 and March 2005, a total of 72
patients were enrolled. The patients’ characteristics are
shown in Table 1. Fifty-five patients were chemotherapy
naive, and the other 17 patients had received only one prior
chemotherapy regimen. There were no differences in pre-
treatment characteristics between the chemotherapy-naive
patients and those who had been treated previously. Twenty-
seven patients had brain metastasis at study enrollment, of
whom 24 patients received gefitinib as a primary therapy for
brain metastases, and three patients received gefitinib after
local therapy for brain lesions, that is, whole-brain irradiation
(1), surgical removal (1), or both (1).
Tumor Response and Survival
Table 2 shows the objective tumor responses. There
was one CR, 39 PRs, and 8 SDs, yielding an overall response
rate of 55.6% (95% CI, 43.4–67.3%) and a disease-control
rate of 66.7% (95% CI, 54.6–77.3%). Chemo-naive patients
tended to show more objective tumor responses (33/55
[60.0%], 95% CI, 45.9–73.0%) than the patients with prior
history of chemotherapy (7/17 [41.2%], 95% CI,
18.4–67.1%), but the difference was not statistically signif-
icant (p  0.264). There were no statistically significant
differences in objective response rate by gender, age (60
years versus 60 years), presence of BAC features, perfor-
mance status (PS 0 or 1–2), or stage (IIIB versus IV).
Of interest, the response of intracranial lesions to ge-
fitinib was closely correlated with that of extracranial lesions.
Of the 24 patients who received gefitinib as a primary
treatment for brain metastases, 12 achieved objective re-
sponses in both intracranial and extracranial sites, and two
had stable disease in intracranial metastases while extracra-
nial lesions showed dramatic response, whereas the other
patients without extracranial lesions did not have intracranial
tumor responses.
With a median follow-up of 23 months, the median
survival time was 19.7 months (95% CI, 18.5–21.0 months)
for all patients, with a 1 year-survival rate of 76.3%. The
median progression-free survival was 5.5 months (95% CI,
4.4–6.5 months), and the median duration of response was
6.8 months (95% CI, 4.7–9.0 months) (Figure 1). Of note, for
chemotherapy-naive patients, the median survival time and
progression-free survival were 20.1 months and 5.9 months,
respectively; corresponding figures were 16.6 months and 2.7
months, respectively, for previously treated patients. Univar-
iate analysis showed that absence of prior chemotherapy was
a significant predictor for progression-free survival (p 
0.017), which was associated with better overall survival with
marginal statistical significance (p  0.080). On the other
hand, performance (0 versus 1–2) was marginally predictive
of progression-free survival (p 0.099) and was significantly
predictive of overall survival (p  0.012) (Figure 2).
Adverse Events
All 72 patients were analyzed for safety. Table 3 lists the
worst National Cancer Institute common toxicity criteria grades
experienced by patients. There were no grade 3 or 4 hematologic
toxicities. Grade 3 nonhematologic toxicities were observed in
seven patients (9.7%), including grade 3 hepatic toxicity in
5.6%, but interstitial pneumonitis or grade 4 toxicities were not
observed. Skin rash was observed in 67 patients (93.1%), but
grade 2 or 3 was observed in only 13 patients (18.1%).
Determinants for Tumor Response
and Survival
To identify the additional predictors for the objective
response and survival, several clinicopathologic characteristics
were analyzed in multivariate logistic regression models and in
multivariate Cox proportional hazards models. No additional
TABLE 1. Baseline Patients’ Characteristics
Total (N  72) First-Line (n  55) Second-Line (n  17)
Patients Characteristics No. of Patients (%) No. of Patients (%) No. of Patients (%) p Value
Median age (range) 54 (29–75) 55 (40–74) 50 (29–75) 0.473
Gender 0.621
Male 6 (8.3) 4 (7.3) 2 (11.8)
Female 66 (91.7) 51 (93.7) 15 (88.2)
ECOG performance status 0.872
0 26 (36.1) 19 (34.5) 7 (41.2)
1 42 (58.3) 33 (60.0) 9 (52.9)
2 4 (5.6) 3 (5.5) 1 (5.9)
Histology 1.000
With BAC features 14 (19.4) 11 (20.0) 3 (17.6)
Without BAC features 58 (80.6) 44 (80.0) 14 (82.4)
Stage 1.000
IIIB 6 (8.3) 5 (9.1) 1 (5.9)
IV 66 (91.7) 50 (90.9) 16 (94.1)
Brain metastases 27 (37.5) 20 (37.0) 7 (41.2)
ECOG, Eastern Cooperative Oncology Group; BAC, bronchioloalveolar carcinoma.
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predictors of the objective tumor response to gefitinib were
found. However, absence of prior chemotherapy was the only
predictor of progression-free survival, and good performance
status and no prior history of chemotherapy were identified to be
the significant predictors of overall survival (Table 4). Of inter-
est, 10 (25%) of 40 patients who had an objective response
experienced grade 2 or 3 skin rash, whereas 1 (12.5%) of 8
patients who had stable disease and 1 (4.2%) of 24 patients who
had progressive disease experienced grade 2 or 3 skin rash. This
suggests an association between grade II/skin rash and objective
tumor response (p 0.034). However, it did not predict overall
survival in univariate and multivariate analysis.
Quality of Life (QoL)
As a baseline, global health status was impaired most,
with a mean score of 53. Physical, role, emotional, and social
functions were also moderately impaired, with mean scores
of 71, 71, 65, and 74, respectively. Cognitive function was
the least impaired, with a mean score of 86. In the QLQ-C30,
fatigue, pain, dyspnea, insomnia, and appetite loss were the
symptoms rated worst, with mean scores ranging from 27 to
38. In the QLQ-LC13, mean scores for dyspnea, cough, and
pain in the chest, arm, shoulder, and other parts ranged from
25 to 36. No scores were different from those of recurrent or
metastatic NSCLC patients when compared against the data
in the EORTC QLQ-30 Reference Values manual. During the
treatment, the statistically significant improvement of pa-
tients’ global health status score, from 56.3 to 66.4 and 71.8,
was observed at 2 and 4 weeks after start of therapy in
responders but not in nonresponders, whose corresponding
scores were from 51.3 to 59.2 and 55.0 (p  0.039). There
were also statistically significant improvements in functional
scales (physical, role, and emotional) and in symptoms scales
(fatigue, dyspnea, insomnia, and appetite loss) during the first
4 weeks of gefitinib therapy in responders. Whereas the
responders sustained their improved quality of life during
gefitinib therapy, such symptoms related to gefitinib; diarrhea
and sore mouth did not deteriorate significantly.
Salvage Chemotherapy on Progression
Out of 55 chemotherapy-naive patients, 53 had progres-
sive disease, of whom 41 received cytotoxic chemotherapy as
second-line treatment, 32 received gemcitabine/vinorelbine,
and 9 received platinum-based regimens (4 gemcitabine/
vinorelbine/cisplatin, 2 gemcitabine/cisplatin, and 3 irinote-
can/cisplatin). Five (16.1%) of 31 evaluable patients treated
with a non–platinum-containing regimen achieved partial
responses, and 4 (44.4%) of 9 patients treated with a plati-
TABLE 2. Clinical Outcomes Among Patient Subgroups (Univariate)
Response Rate (CR  PR) Progression-Free Survival Overall Survival
No. of Patients (%) p Median (mo, 95% CI) Log-Rank p Median (mo, 95% CI) Log-Rank p
Total (n  72) 40 (55.6) 5.5 (4.4–6.5) 9.7 (18.5–21.0)
Gender 0.396 0.118 0.133
Male (n  6) 2 (33.3) 1.6 (0.4–2.9) 14.8 (10.9–18.9)
Female (n  66) 38 (57.6) 5.5 (4.6–6.4) 20.2 (18.1–22.4)
Age 0.316 0.451 0.803
60 (n  48) 29 (60.4) 5.9 (3.4–8.5) 20.1 (14.8–25.5)
60  (n  24) 11 (45.8) 4.1 (1.6–6.5) 19.7 (16.7–22.7)
BAC features 0.767 0.798 0.166
Yes (n  14) 7 (50.0) 5.4 (1.8–9.0) 21.0 (13.1–28.9)
No (n  58) 33 (56.9) 5.5 (4.6–6.4) 19.6 (17.2–22.0)
ECOG performance
status
0.784 0.099 0.012
0 (n  26) 15 (57.7) 7.4 (4.5–10.2) Not reached
1 or 2 (n  46) 25 (54.3) 4.8 (3.0–6.7) 16.4 (10.9–22.0)
Stage 0.396 0.823 0.281
IIIB (n  6) 2 (33.3) 4.1 (0.0–10.0) 19.1 (4.6–33.7)
IV (n  66) 38 (57.6) 5.5 (4.5–6.4) 19.4 (16.2–22.5)
Prior chemotherapy 0.264 0.017 0.080
Yes (n  17) 7 (41.2) 2.7 (0.0–5.6) 16.6 (11.5–21.6)
No (n  55) 33 (60.0) 5.9 (3.9–7.8) 20.1 (18.9–23.1)
FIGURE 1. Kaplan–Meier estimates of progression-free sur-
vival and overall survival for all patients from start of treat-
ment. Tick marks indicate censored data.
DH Lee et al. Journal of Thoracic Oncology • Volume 1, Number 9, November 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer968
num-based regimen achieved partial response. Only 2 (7.1%)
of 28 evaluable patients responded to the third-line chemo-
therapy.
DISCUSSION
We observed a very promising objective response rate
(60.0% for chemotherapy-naive and 41.2% for previously
treated patients; overall 55.6%) and survival outcomes with a
median survival time of 19.7 months and a 1-year survival
rate of 76.3% in never-smokers with adenocarcinoma of the
lung. These results highly contrast with most first-line cyto-
toxic chemotherapy trials, which have reported median sur-
vival time of only 8 to 10 months and 1-year survival rates of
about 30 to 40% for the previously untreated patient popula-
tion.16,17 In a second-line treatment setting, docetaxel gave
only an extra 2.4 months survival.18,19 However, we should
TABLE 3. The Worst National Cancer Institute Common Toxicity Criteria Grade Toxicities Per Patient
Adverse Effect Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Hematologic toxicity: no. of patients (%)
Leukopenia 63 (87.5) 9 (12.5) 0 0 0
Neutropenia 56 (77.8) 13 (18.1) 3 (4.2) 0 0
Anemia 43 (59.7) 27 (37.5) 2 (2.83) 0 0
Thrombocytopenia 69 (95.8) 3 (4.2) 0 0 0
Nonhematologic toxicity: no. of patients (%)
Rash 5 (6.9) 54 (75.0) 11 (15.3) 2 (2.8) 0
Dry skin 13 (18.1) 26 (36.1) 33 (45.8) 0 0
Stomatitis 19 (26.4) 30 (41.7) 23 (31.9) 0 0
Pruritus 23 (31.9) 37 (51.4) 12 (16.7) 0 0
Anorexia 32 (44.4) 28 (38.9) 11 (15.3) 1 (1.4) 0
Asthenia 36 (50.0) 25 (34.7) 10 (13.9) 1 (1.4) 0
Nausea/vomiting 50 (69.4) 17 (23.6) 4 (5.6) 1 (1.4) 0
Diarrhea 31 (43.1) 35 (48.6) 6 (8.3) 0 0
Elevated AST/ALT 42 (58.3) 18 (25.0) 8 (11.1) 4 (5.6) 0
Neuropathy 54 (75.0) 17 (23.6) 0 (0.0) 1 (1.4) 0
Infection 47 (65.3) 10 (13.9) 15 (20.8) 0 0
TABLE 4. Multivariate Cox Proportional Hazard Analyses for Survival
Clinicopathologic Factors
Progression-Free Survival Overall Survival
Multivariate
p Value
Hazard Ratio
(95% CI)
Multivariate
p Value
Hazard Ratio
(95% CI)
Factors in the final model
No. of prior chemotherapy, 0 vs. 1 0.018 2.02 (1.13–3.60) 0.042 2.14 (1.03–4.44)
ECOG performance status, 0 vs. 1 or 2 0.058† 0.005 2.97 (1.38–6.40)
Factors not in the final model
Gender, female vs male 0.082 0.086
Age, 60 vs. 60 yr 0.646 0.672
Stage of disease, IIIB vs. IV 0.735 0.316
Histology, without vs. with BAC features 0.870 0.173
†Not included in the final model for progression-free survival. CI, confidence interval.
FIGURE 2. Kaplan–Meier estimates of overall
survival among patient subgroups. (A) Perfor-
mance status (ECOG PS, 0 versus 1 or 2). (B)
Prior history of chemotherapy (chemotherapy
naive versus previously treated). Tick marks in-
dicate censored data. ECOG, Eastern Coopera-
tive Oncology Group; PS, performance status.
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take extra precaution in interpreting the data at face value,
because never-smokers tend to survive better than smok-
ers,20,21,22 and female patients have shown to survive longer
than male patients.23,24 In addition, Korean patients, like
Japanese patients,25 have shown to survive longer than Amer-
ican or European patients for unknown reasons.
In this study, 12 of 24 patients with evaluable brain
lesions achieved objective tumor responses in the brain le-
sions, all corresponding with the objective tumor responses
noted at the extracranial sites. This finding strongly supports
the notion that the brain is no longer a sanctuary site when
effective systemic treatment is employed, whether it is che-
motherapy or targeted-therapy agents such as gefitinib. It
carries a significant clinical implication: never-smokers with
adenocarcinoma of the lung can be treated with gefitinib
regardless of their brain metastasis status.
Recently, a strong association was reported between
responses to gefitinib or other tyrosine kinase inhibitors and
EGFR gene mutations as well as the EGFR and HER2 gene
copy numbers.26–32 On the other hand, KRAS mutations,
which occur more commonly in individuals with a history of
substantial cigarette use, were associated with a lack of
sensitivity to gefitinib.33,34 As shown in the present study, a
clinical parameter alone, that is, never-smokers with adeno-
carcinoma of the lung, seems to be a very useful criterion in
selecting patients who would benefit most from gefitinib
therapy, at least in Korea.
In the current study, we could not find any significant
association between such clinical parameters as gender or
bronchioloalveolar features and the outcome of gefitinib ther-
apy. This might be because only a few male patients were
enrolled in this study, and there were also only a few patients
who had tumors with bronchioloalveolar features. Neverthe-
less, good performance status and no prior chemotherapy
were the two most significant predictors of survival, a finding
quite consistent with what is intuitively anticipated and with
what has been reported in the literature.35,36
In conclusion, we demonstrated that gefitinib is highly
active for adenocarcinoma of the lung in Korean never-smokers.
Further randomized trials are warranted to delineate the role of
gefitinib as a first-line treatment in this subset of selected patients
as compared with standard chemotherapy.
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